SB 649 requires West Virginia Medicaid to cover home blood pressure monitoring devices for specific enrollees: pregnant individuals or those within 12 months postpartum who have been diagnosed with uncontrolled hypertension. The bill mandates that covered devices must be validated by the U.S. Blood Pressure Validated Listing and includes coverage for an extra blood pressure cuff. Medicaid providers must also receive reimbursement for related services, such as patient training, interpreting readings, and delivering co-interventions. This policy directly affects Medicaid recipients with hypertension during pregnancy or postpartum, expanding access to essential monitoring tools.
HB 5260 adds "edible" as an allowable form of medical cannabis in West Virginia, with strict requirements for safety and regulation. It requires processors to obtain bureau approval for each edible product, mandates specific shapes (like squares or circles), limits edibles to lozenges or gelatins, and caps THC content at 10mg per serving with a 15% potency variance. The bill prohibits color additives in edibles and requires all medical cannabis dispensing to be reported to the state's controlled substance monitoring database. This directly affects patients using medical cannabis, caregivers, and licensed processors who must comply with these new edible-specific rules.
HB 5563 requires licensed healthcare providers in West Virginia to refer patients meeting organ transplant criteria to a transplant center within three calendar days of documenting that need in the medical record. It exempts referrals only when a specific medical contraindication is documented. The Department of Health must collect and report annual data on referral timelines, including average wait times, compliance rates, and rural disparities. This law directly affects hospitals, transplant centers, and patients awaiting organ transplants by standardizing referral processes. The bill does not alter federal organ allocation policies or clinical eligibility standards.
HB 5413 creates a Central Abuse Registry managed by the West Virginia State Police to track individuals convicted of abuse, neglect, or misappropriation of property involving children, incapacitated adults, or adults receiving behavioral health services in specific settings like residential care facilities, day care centers, or home care. It requires registrants to provide personal details (name, DOB, SSN) and pay an annual $125 fee to the circuit clerk, with fees funding mental health services for State Police employees. The registry combines existing requirements, so those already registering as sex offenders only pay one $125 fee instead of separate fees. Failure to pay the fee does not violate supervised release, but unpaid fees may result in a recorded judgment lien.
HB 4981 designates psychiatric hospitals treating exclusively civil and forensic patients (over 95% court-ordered civil/forensic cases from state custody) as "state-designated facilities" for Medicaid funding purposes. This change allows these specific hospitals to qualify for Medicaid reimbursement under federal rules, rather than being excluded as "state-designated" under current tax code. The bill amends tax provisions to ensure revenue collected from eligible hospitals (via a 0.75% tax on gross receipts) flows directly into a Medicaid funding account. It directly affects licensed psychiatric hospitals meeting the strict patient-mix criteria, enabling them to access Medicaid program funds they previously could not.
HB 4629 amends West Virginia's tobacco sales law to allow institutions of higher education to distribute tobacco cessation products to individuals aged 18-21 for research purposes. This directly affects college/university research programs approved by institutional review boards (IRBs) that study tobacco cessation or prevention. The key provision creates an exception to the general 21+ age restriction, requiring all such distributions to occur within medically supervised, IRB-approved research programs. The bill changes the policy by permitting this specific age group access for legitimate medical research, while maintaining penalties for unauthorized sales to minors.
